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to RAF inhibitors; thus, it will be 
worthwhile to examine changes in Axl 
expression in cell line–based models 
of resistance to RAF inhibitors, as well 
as in samples from relapsed patients. In 
summary, Gas6–Axl signaling may be 
a signaling “axis of evil” in melanoma, 
and it should be investigated further as a 
“druggable” pathway.
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Infantile Hemangioma Research: 
Looking Backward and forward
Ilona J. Frieden1
This is a remarkable time to be a student of infantile hemangiomas (IHs). IH is a 
common tumor, estimated to occur in approximately 4% of infants. Studied for 
many decades, the acquisition of knowledge and pace of IH research are accel-
erating. The article by Greenberger et al. in this issue is a welcome addition to 
the literature. It examines rapamycin as a possible treatment for IH that could 
potentially be curative because suppression of self-renewal of stem cells might 
deplete hemangiomas of the stem cells from which they originate. However, 
before we get too enthusiastic about using rapamycin for IHs, it is important to 
reflect on lessons learned from previous hemangioma therapies.
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Infantile hemangioma research  
in the 20th century
Although there was evidence as 
far back as the late 1930s that 
infantile hemangioma (IH) involuted 
spontaneously, studies describing the 
natural history of IHs published in the 
1960s more clearly delineated the 
characteristic natural history of rapid 
growth followed by gradual involu-
tion. X-irradiation therapy, an effective 
treatment for hemangiomas, was used 
widely from 1930 to 1950 (Mulliken 
and Young, 1988). Starting in the 1950s, 
prominent physicians—among them 
the founders of the subspecialty of pedi-
atric dermatology, Alvin Jacobs and 
Sidney Hurwitz—decried the use of 
X-irradiation and attempts at preemptive 
surgical removal, advocating a hands-
off approach. Why, after all, would you 
treat something that would go away on 
its own? This was sage advice, but it had 
its limitations. Although most heman-
giomas involute without leaving major 
sequelae, a significant minority are 
problematic.
An important therapeutic break-
through came in the mid-1960s, when 
systemic corticosteroids were found 
to be an effective treatment. Despite 
their many potential side effects, 
prednisolone and other corticosteroids 
became a mainstay of treatment for 
those hemangiomas severe enough to 
require systemic therapy. Treatment of 
IH causing medical morbidities (e.g., 
amblyopia or airway disease) was 
clearly necessary. Less clear, however, 
was the approach for hemangiomas 
that are not medically endangering but 
are arguably life-altering—leaving scar-
ring or permanent distortion of impor-
tant anatomic structures of the face, 
such as the nose and lips.
In 1982, Mulliken and Glowacki 
proposed a biologic classification of 
vascular birthmarks into “hemangio-
mas” and “vascular malformations.” 
This was a major conceptual break-
through that helped to clearly delin-
eate IHs as an entity distinct from 
other vascular birthmarks (particularly 
venous malformation, with which it 
was often lumped, under the diag-
nosis of “cavernous hemangioma”) 
(Mulliken and Glowacki, 1982). Like 
many other important ideas, this one 
seems obvious in retrospect. At the 
time, however, nosologic confusion 
was a major obstacle to understand-
ing the biology of IH; this confusion 
hampered efforts to define optimal 
treatments. A chronic lack of fund-
ing also hindered research. Without 
funding from the National Institutes 
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of Health or pharmaceutical interest, 
research continued to consist mainly 
of case reports and small case series.
By the late 1980s and early 1990s, 
multidisciplinary vascular anomalies 
centers were being established both in 
the United States and internationally. 
These centers began to concentrate 
referral patients and increase collec-
tive expertise regarding hemangiomas 
as well as other vascular anomalies. 
Interested physicians and scientists 
began to hold informal workshops, 
and in 1992, the International Society 
for the Study of Vascular Anomalies 
was established. Other developments 
that spurred interest in hemangiomas 
included the trend toward increasing 
patient self-advocacy, which led many 
parents of infants with IHs to question 
the standard advice “not to worry” and 
instead look for other answers. Patient-
support organizations were formed.
Advances in laser therapy, particu-
larly the pulsed dye laser (PDL), which 
became commercially available in 
1989, added another potential treat-
ment for IHs. This advance, in turn, 
led many physicians to reconsider 
whether there might be better therapies 
(including PDL) to treat hemangiomas. 
In 1991, Ezekowitz et al. reported the 
use of interferon (IFN)-α as a novel 
hemangioma therapy; in 1992 they 
published a case series of 20 patients, 
most of whom had failed systemic cor-
ticosteroid therapy. Recognition of the 
need for better therapies is attested to 
by more than a dozen articles pub-
lished within five years after the initial 
reports of IFN therapy (Ezekowitz et al., 
1992). Unfortunately, another lesson 
was learned from the IFN experience: 
in the late 1990s, severe neurotoxicity 
was recognized as a side effect, occur-
ring in up to 20% of patients.
IH research in the 21st century
The pace of hemangioma research 
has increased significantly in the 21st 
century (Figure 1). In January 2000, 
North et al. published their seminal 
observation that, unlike other vascular 
tumors or vascular malformations, IHs 
stain with the immunohistochemical 
marker Glut-1 (North et al., 2000). 
This and the many observations that 
followed revolutionized the way we 
think about hemangiomas. We now 
know that IH is not a tumor of ordi-
nary cutaneous blood vessels that have 
“run amok” but, rather, a growth with a 
unique vascular phenotype. The dem-
onstration of the remarkable similari-
ties between IH and placental blood 
vessels led several investigators to look 
more closely at the cells of origin of IH. 
We now recognize that IH may be not 
solely a disorder of angiogenesis (i.e., 
the sprouting of vessels from exist-
ing ones) but in fact due—at least in 
part—to a disorder of vasculogenesis 
(i.e., de novo formation of new blood 
vessels from circulating stem cells) 
(Boscolo and Bischoff, 2009; Dadras 
et al., 2004). The progenitor cells of IH 
have many pluripotent qualities, with 
features of myeloid, monocytic, endo-
thelial, and even neural crest differen-
tiation (Itinteang et al., 2010; Kleinman 
et al., 2007). Therefore, IHs may rep-
resent a growth of primitive mesen-
chymal cells in a state of arrested 
development. Attempts to character-
ize the nature of the progenitor cells 
of hemangiomas continue. The devel-
opment of sustainable in vitro and ex 
vivo models was another major step. In 
2000, Tan et al. reported such a model, 
with tissue explants of IH embed-
ded in fibrin gel (Tan et al., 2000). In 
2008, Khan et al. reported the creation 
of a sustainable ex vivo model in nude 
mice. In this model, used in the cur-
rent study, isolation of multipotential 
stem cells from surgically removed IH 
tissue gave rise to hemangioma-like 
lesions, retaining phenotype and even-
tually involuting with decreased blood 
vessels and increased adipocytes, 
mimicking the natural history of IHs 
(Khan et al., 2008).
Over the past decade, many studies 
have increased our understanding of 
the clinical characteristics of IHs. We 
now know that hemangiomas are not 
randomly distributed. We have also 
moved beyond the traditional mor-
phologic descriptions of IH as super-
ficial, deep, and mixed to recognize 
two other important patterns of hem-
angiomas: those that are spatially con-
fined, or “localized,” and those with 
a territorial distribution, or “segmen-
tal” (Chiller et al., 2002; Waner et al., 
2003). The patterns of segmental hem-
angiomas of the face were found to cor-
respond to embryologic prominences 
(such as the maxillary and mandibular 
placodes) that arise early in embryo-
logic development (Haggstrom et al., 
2006b; Waner et al., 2003). Like their 
smaller, more localized counterparts, 
segmental IHs have all the immunohis-
tochemical and molecular features of 
other IHs, including rapid growth and 
spontaneous involution, but the recog-
nition of these patterns of distribution 
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Figure 1. results of a Pubmed search on 1 august 2011. Search terms: hemangioma[majr:noexp] 
OR (hemangioendothelioma[majr:noexp]) OR (hemangioma, capillary[majr:noexp]) OR 
(hemangioma, cavernous[majr:noexp]). Limits: All infant: birth–23 months. Subsearches were 
with “therapy” as a subheading and with “physiopathology,” “pathology,” and “physiology” and 
keyword “pathogene*” as subheadings.
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and the increased appreciation that 
IHs can have associated structural 
malform ations (e.g., PHACE syndrome) 
provided further clues that segmental 
IHs arise via an early error in embryo-
logic development that is permissive for 
hemangioma progenitor cell growth.
A study of early hemangioma growth 
by the Hemangioma Investigator 
Group (HIG) added yet another 
clue to the developmental nature of 
hemangiomas. Both localized and 
segmental hemangiomas, rather than 
having a lateral growth phase (as one 
might expect from a conventional 
tumor), “mark out their territory” 
and grow volumetrically (Chang et 
al., 2008). Other HIG studies have 
helped to identify the clinical charac-
teristics that best predict the greatest 
risk for complications. A prospec-
tive cohort study of more than 1,000 
infants demonstrated that segmental 
hemangiomas have a higher risk of 
complications, need for treatment, 
and associated structural anomalies 
(Haggstrom et al., 2006a). Current 
HIG studies include the creation of a 
disease-severity score and the creation 
of an instrument for measuring the 
impact on parental quality of life.
This history would not be complete 
without mention of one of the most 
remarkable recent developments: 
the serendipitous observation that 
propranolol is an effective treatment 
for IHs. In the three years since June 
2008 when Leaute-Labreze et al. first 
reported their findings in a letter to 
the New England Journal of Medicine, 
more than 140 articles regarding 
β-blocker therapy for IHs have been 
published, nearly all reporting positive 
results (Leaute-Labreze et al., 2008). 
Other β-blockers, such as acebutolol 
and nadolol, may also be effective, 
and preliminary reports of a topical 
β-blocker, timolol, suggest that it may 
be helpful for smaller, more superfi-
cial hemangiomas. Experience thus far 
with propranolol for IHs again points 
to caution when treating young infants 
with hemangiomas—one might have 
expected bradycardia or hypotension 
as possible side effects, but, instead, 
hypoglycemia has emerged as a rare 
but potentially serious side effect.
Future therapies
Greenberger and colleagues’ study 
(2011, this issue) regarding the effects 
of rapamycin on an in vitro model of 
IH is a welcome step in this journey. 
Rapamycin appears to target HemSC 
via a mechanism distinct from cortico-
steroids, suggesting that the drugs used 
together (perhaps at lower doses) could 
enhance their effects. Interestingly, this 
report does not mention whether pro-
pranolol or other β-blockers have simi-
lar effects—something that would be 
of great interest because propranolol is 
becoming a first-line therapy in many 
centers. The finding of a loss of stem 
cell properties should be of particular 
interest because such an effect might 
conceivably offer a cure without the 
rebound growth that can be a problem, 
for a significant minority of patients, in 
both steroid and β-blocker use. The tar-
get of rapamycin (mTOR) is a kinase of 
the phosphoinositide 3-kinase signaling 
pathway. It is one of the most important 
intracellular mediators of the activity of 
growth factor receptors, including vas-
cular endothelial growth factor (VEGF). 
Although preliminary evidence suggests 
that rapamycin, given systemically or 
applied topically, is beneficial under 
other conditions with vascular over-
growth (such as angiofibromas in tuber-
ous sclerosis), its activity would not nec-
essarily be anticipated in IH. In addition 
to its possible therapeutic implications, 
the finding of its effects in a laboratory 
model of IH should certainly be taken 
as a clue to looking closely at its effects 
on VEGF and VEGF receptors, which 
have already been shown to play a role 
in hemangioma growth (Jinnin et al., 
2008).
The idea of yet another drug that 
might be useful in treating IHs is excit-
ing, but the history of unanticipated 
problems with previous hemangioma 
therapies makes it important to inject 
a cautionary note. We have known 
for decades that not all hemangiomas 
need treatment; enthusiasm for a new 
therapy should never let us lose sight of 
this important fact. Given the tremen-
dous heterogeneity in size, location, 
and growth potential, the development 
of validated disease-severity scores 
should help to ensure that we com-
pare hemangiomas of similar severity 
rather than lumping together disparate 
IHs. Equally important is the recogni-
tion that the target population for hem-
angioma therapy is infants who both 
are undergoing rapid somatic growth 
and have rapidly maturing organs—in 
particular, the central nervous system. 
Infants may thus be particularly vul-
nerable to side effects that are either 
unanticipated (e.g., spastic diple-
gia with IFN) or rare in older patients 
(e.g., hypoglycemia with propranolol). 
Rapamycin (sirolimus), a calcineurin 
inhibitor, has many potential side 
effects and has boxed warnings regard-
ing risk of immunosuppression and risk 
of developing lymphoma and other 
malignancies. Experience regarding 
its toxicities in infants is limited (Blatt 
et al., 2010). It is generally not used 
in combination with corticosteroids 
because of the potential for additive 
immunosuppressive effects. Do these 
concerns mean we should not con-
sider rapamycin a potential treatment? 
Not necessarily—but we should hold 
ourselves to a higher standard than in 
decades past and study this and future 
hemangioma therapies in an evidence-
based manner.
Clinical Implications
•  Multipotential stem cells from surgically removed infantile 
hemangioma (IH) tissue give rise to hemangioma-like lesions that 
mimic the natural history of IH.
•  Based on research reported in this article, rapamycin may benefit 
infants with IH.
•  Even if rapamycin does benefit some infants with IH, its potential for 
toxicity appears to be greater than that of propranolol.
•  There is a severe lack of high-quality randomized controlled trials that 
assess the effects of treatment for IH.
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A recent Cochrane analysis high-
lights the deficiencies of previous 
hemangioma treatment. More than 
four decades after corticosteroids were 
found to be effective in treating IHs and 
two decades after the introduction of 
PDL for IHs, the authors of this meta-
analysis were able to find only four 
randomized controlled trials (RCTs), 
involving only 271 patients, to ana-
lyze (Leonardi-Bee et al., 2011). They 
found insufficient evidence to support 
existing interventions, such as cortico-
steroids and laser, and concluded that 
there is “a need for further high-quality 
RCTs to validate the findings from these 
studies, and RCTs to assess the effect of 
other treatments, in particular relating 
to propranolol.” Fortunately, at least 10 
treatment studies for IH are currently 
listed at ClinicalTrials.gov, includ-
ing a large international RCT compar-
ing propranolol and placebo, and it is 
hoped that more will follow. We owe 
it to infants with IHs and the scientific 
community to study this disease and its 
potential therapies rigorously.
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